Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and agingLinda S. Steelman, James A. McCubrey, William H. Chappell et al.|Aging|2011Cited by 707
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human HealthWilliam H. Chappell, James A. McCubrey, Linda S. Steelman et al.|Oncotarget|2011Cited by 579
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome ResistanceJames A. McCubrey, Alberto M. Martelli, Giuseppe Montalto et al.|Oncotarget|2012Cited by 317
Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.James A. McCubrey, Alberto M. Martelli, Linda S. Steelman et al.|Oncotarget|2012Cited by 307
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic interventionNicole D. Armstrong, James A. McCubrey, Melissa L. Sokolosky et al.|Oncotarget|2014Cited by 246